Bharat Biotech acquires licence for GSK’s Shigella vaccine development
Pharmaceutical Technology
JUNE 13, 2025
The technology utilises outer membrane vesicles (OMVs) to deliver antigens, often eliminating the need for adjuvants while triggering the immune response. The partnership strengthens GSK’s current relationship with the Indian company, which began with a product transfer and licence agreement in 2021 for the malaria vaccine, RTS,S.
Let's personalize your content